It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Microvascular disease and rarefaction are key pathological hallmarks of hypertension. The retina uniquely allows direct, non-invasive investigation of the microvasculature. Recently developed optical coherence tomography angiography now allows investigation of the fine retinal capillaries, which may provide a superior marker of overall vascular damage. This was a prospective cross-sectional study to collect retinal capillary density data on 300 normal eyes from 150 hypertensive adults, and to investigate possible associations with other organ damage markers. The average age of participants was 54 years and there was a greater proportion of males (85; 57%) than females. Multivariate, confounder adjusted linear regression showed that retinal capillary rarefaction in the parafovea was associated with increased pulse wave velocity (β = − 0.4, P = 0.04), log-albumin/creatinine ratio (β = − 0.71, P = 0.003), and with reduced estimated glomerular filtration rate (β = 0.04, P = 0.02). Comparable significant associations were also found for whole-image vascular-density, for foveal vascular-density significant associations were found with pulse wave velocity and estimated glomerular filtration rate only. Our results indicate that retinal capillary rarefaction is associated with arterial stiffness and impaired kidney function. Retinal capillary rarefaction may represent a useful and simple test to assess the integrated burden of hypertension on the microvasculature irrespective of current blood pressure levels.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Commonwealth Scientific and Industrial Research Organisation (CSIRO) Health and Biosecurity, Wembley, Australia (GRID:grid.1016.6) (ISNI:0000 0001 2173 2719); Australian E-Health Research Centre, Perth, Australia (GRID:grid.467740.6) (ISNI:0000 0004 0466 9684)
2 University of Western Australia, Dobney Hypertension Centre, School of Medicine - Royal Perth Hospital Unit/Medical Research Foundation, Perth, Australia (GRID:grid.1012.2) (ISNI:0000 0004 1936 7910)
3 University of Western Australia, Dobney Hypertension Centre, School of Medicine - Royal Perth Hospital Unit/Medical Research Foundation, Perth, Australia (GRID:grid.1012.2) (ISNI:0000 0004 1936 7910); Royal Perth Hospital, Departments of Cardiology and Nephrology, Perth, Australia (GRID:grid.416195.e) (ISNI:0000 0004 0453 3875)
4 Perron Institute for Neurological and Translational Science, Perth, Australia (GRID:grid.482226.8) (ISNI:0000 0004 0437 5686)
5 University of Notre Dame Australia, School of Medicine, Fremantle, Australia (GRID:grid.266886.4) (ISNI:0000 0004 0402 6494)
6 University of Western Australia, Dobney Hypertension Centre, School of Medicine - Royal Perth Hospital Unit/Medical Research Foundation, Perth, Australia (GRID:grid.1012.2) (ISNI:0000 0004 1936 7910); Royal Perth Hospital, Departments of Cardiology and Nephrology, Perth, Australia (GRID:grid.416195.e) (ISNI:0000 0004 0453 3875); Baker Heart and Diabetes Institute, Neurovascular Hypertension and Kidney Disease Laboratory, Melbourne, Australia (GRID:grid.1051.5) (ISNI:0000 0000 9760 5620)